Shares of Gilead Sciences, Inc. (NASDAQ:GILD) have earned a consensus recommendation of “Buy” from the twenty-eight research firms that are covering the stock, MarketBeat.com reports. Ten research analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $99.86.
Several research firms have recently weighed in on GILD. Jefferies Financial Group restated a “buy” rating and issued a $80.00 target price on shares of Gilead Sciences in a research report on Friday, May 7th. Sanford C. Bernstein upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $80.00 target price on the stock in a research report on Thursday, April 1st. SVB Leerink raised their target price on Gilead Sciences from $72.00 to $74.00 and gave the company an “outperform” rating in a research report on Friday, April 30th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Friday, April 30th. Finally, Zacks Investment Research raised Gilead Sciences from a “sell” rating to a “hold” rating and set a $69.00 price target for the company in a report on Wednesday, May 5th.
In related news, Director Richard James Whitley sold 20,282 shares of Gilead Sciences stock in a transaction on Monday, May 3rd. The stock was sold at an average price of $64.57, for a total value of $1,309,608.74. Following the completion of the transaction, the director now directly owns 51,404 shares in the company, valued at $3,319,156.28. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.12% of the company’s stock.
Gilead Sciences stock traded up $0.17 during midday trading on Tuesday, hitting $69.30. 3,969,293 shares of the company were exchanged, compared to its average volume of 6,840,915. The company has a market cap of $86.91 billion, a price-to-earnings ratio of 301.32, a PEG ratio of 0.64 and a beta of 0.38. The stock’s fifty day simple moving average is $67.18. The company has a debt-to-equity ratio of 1.55, a current ratio of 1.37 and a quick ratio of 1.18. Gilead Sciences has a fifty-two week low of $56.56 and a fifty-two week high of $78.94.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, April 29th. The biopharmaceutical company reported $2.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.06 by $0.02. The company had revenue of $6.42 billion for the quarter, compared to the consensus estimate of $6.78 billion. Gilead Sciences had a return on equity of 51.91% and a net margin of 1.18%. Equities research analysts expect that Gilead Sciences will post 7.07 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Tuesday, June 29th. Investors of record on Tuesday, June 15th were issued a $0.71 dividend. The ex-dividend date of this dividend was Monday, June 14th. This represents a $2.84 dividend on an annualized basis and a yield of 4.10%. Gilead Sciences’s dividend payout ratio (DPR) is presently 40.06%.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.
Featured Story: Market Capitalization and Individual Investors
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.